(FM) Medicina Interna

2023

1. Advancing with cancer immunotherapeutics: CD29+ regulatory T cell antagonism

   Gut

2. Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (Nature Communications, (2019), 10, 1, (3126), 10.1038/s41467-019-11004-3)

   Nature Communications

3. Corrigendum to “EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma” [J Hepatol (79) (2023) 181–208, (S016882782300185X), (10.1016/j.jhep.2023.03.010)]

   Journal of Hepatology

4. Corrigendum: Role of NAFLD on the health related QoL response to lifestyle in patients with metabolic syndrome: The PREDIMED plus cohort(Front. Endocrinol., (2022), 13, (868795), 10.3389/fendo.2022.868795)

   Frontiers in Endocrinology

5. Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)

   Frontiers in Pharmacology

6. Diagnosis, evaluation and monitoring of acute hepatic porphyria

   Medicina Clinica

7. Editorial: Long non-coding RNAs in viral infections and immunity

   Frontiers in Immunology

8. Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies(Front. Immunol., (2023), 13, (1044025), 10.3389/fimmu.2022.1044025)

   Frontiers in Immunology

9. From the Editor's Desk.

   Journal of Hepatology

10. From the Editor's Desk.

    Journal of Hepatology

11. From the Editor's Desk..

    Journal of Hepatology

12. From the Editor's Desk...

    Journal of Hepatology

13. From the Editor's Desk…

    Journal of Hepatology

14. From the Editor's Desk…

    Journal of Hepatology

15. From the Editor's Desk…

    Journal of Hepatology

16. From the Editor's Desk…

    Journal of Hepatology

17. From the Editor's Desk…

    Journal of Hepatology

18. From the Editor's Desk…

    Journal of Hepatology

19. From the Editor's Desk…

    Journal of Hepatology

20. Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients’ prognosis and pharmacotherapy: MASLD: new pathogenic mechanisms, risk assessment tools and drug therapies

    Journal of Physiology and Biochemistry